flecainide has been researched along with Heart Defects, Congenital in 7 studies
Flecainide: A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS.
flecainide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid with the primary amino group of piperidin-2-ylmethylamine. An antiarrhythmic agent used (in the form of its acetate salt) to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart).
Heart Defects, Congenital: Developmental abnormalities involving structures of the heart. These defects are present at birth but may be discovered later in life.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Flecainide is a rare cause of hypersensitivity pneumonitis, and few cases have been reported." | 6.41 | Flecainide-associated pneumonitis with acute respiratory failure in a patient with the LEOPARD syndrome. ( Fuhrman, C; Perchet, H; Robain, A, 2000) |
| "The use of flecainide and propafenone for medical cardioversion of atrial fibrillation (AF) and atrial flutter/intra-atrial reentrant tachycardia (IART) is well-described in adults without congenital heart disease (CHD)." | 4.31 | Medical cardioversion of atrial fibrillation and flutter with class IC antiarrhythmic drugs in young patients with and without congenital heart disease. ( Alexander, ME; Bezzerides, VJ; DeWitt, ES; Dionne, A; Eberly, LM; Mah, DY; O'Leary, ET; Przybylski, R; Triedman, JK; Walsh, EP, 2023) |
| "Flecainide is a rare cause of hypersensitivity pneumonitis, and few cases have been reported." | 2.41 | Flecainide-associated pneumonitis with acute respiratory failure in a patient with the LEOPARD syndrome. ( Fuhrman, C; Perchet, H; Robain, A, 2000) |
| "Flecainide is a safe and effective antiarrhythmic medication, even for children with underlying CHD." | 1.46 | The Safety and Effectiveness of Flecainide in Children in the Current Era. ( Cunningham, T; Franciosi, S; Jeremiasen, I; Morris, R; Sanatani, S; Sherwin, E; Uzun, O; Wong, A, 2017) |
| "Flecainide was administered in 229 pts (6." | 1.42 | Flecainide use in children with cardiomyopathy or structural heart disease. ( delaUz, C; Kim, JJ; Krenek, M; Lupo, PJ; Miyake, C; Moffett, BS; Valdes, SO, 2015) |
| "Flecainide was effective in all 7 patients after an infusion duration of 3." | 1.32 | Intravenous flecainide for the treatment of junctional ectopic tachycardia after surgery for congenital heart disease. ( Bronzetti, G; Formigari, R; Frascaroli, G; Gargiulo, G; Giardini, A; Picchio, FM, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Przybylski, R | 1 |
| Eberly, LM | 1 |
| Alexander, ME | 1 |
| Bezzerides, VJ | 1 |
| DeWitt, ES | 1 |
| Dionne, A | 1 |
| Mah, DY | 1 |
| Triedman, JK | 1 |
| Walsh, EP | 1 |
| O'Leary, ET | 1 |
| Cunningham, T | 1 |
| Uzun, O | 1 |
| Morris, R | 1 |
| Franciosi, S | 1 |
| Wong, A | 1 |
| Jeremiasen, I | 1 |
| Sherwin, E | 1 |
| Sanatani, S | 1 |
| Sakurai, K | 1 |
| Takahashi, K | 1 |
| Nakayashiro, M | 1 |
| Enzensberger, C | 1 |
| Kreymborg, KG | 1 |
| Valeske, K | 1 |
| Apitz, C | 1 |
| Akintürk, H | 1 |
| Schranz, D | 1 |
| Axt-Fliedner, R | 1 |
| Moffett, BS | 1 |
| Valdes, SO | 1 |
| Lupo, PJ | 1 |
| delaUz, C | 1 |
| Miyake, C | 1 |
| Krenek, M | 1 |
| Kim, JJ | 1 |
| Bronzetti, G | 1 |
| Formigari, R | 1 |
| Giardini, A | 1 |
| Frascaroli, G | 1 |
| Gargiulo, G | 1 |
| Picchio, FM | 1 |
| Robain, A | 1 |
| Perchet, H | 1 |
| Fuhrman, C | 1 |
1 review available for flecainide and Heart Defects, Congenital
| Article | Year |
|---|---|
Flecainide-associated pneumonitis with acute respiratory failure in a patient with the LEOPARD syndrome.
Topics: Abnormalities, Multiple; Acute Disease; Anti-Arrhythmia Agents; Flecainide; Heart Defects, Congenita | 2000 |
6 other studies available for flecainide and Heart Defects, Congenital
| Article | Year |
|---|---|
Medical cardioversion of atrial fibrillation and flutter with class IC antiarrhythmic drugs in young patients with and without congenital heart disease.
Topics: Adolescent; Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Electric Countershoc | 2023 |
The Safety and Effectiveness of Flecainide in Children in the Current Era.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiomyopathies; Child, Preschool; Cohort Studies; Fe | 2017 |
Combined flecainide and sotalol therapy for multifocal atrial tachycardia in cardio-facio-cutaneous syndrome.
Topics: Anti-Arrhythmia Agents; Drug Therapy, Combination; Ectodermal Dysplasia; Electrocardiography; Facies | 2018 |
Management of idiopathic giant dilatation of the right atrium with subsequent atrial tachycardia.
Topics: Adult; Anti-Arrhythmia Agents; Digoxin; Echocardiography; Female; Fetal Diseases; Flecainide; Heart | 2013 |
Flecainide use in children with cardiomyopathy or structural heart disease.
Topics: Anti-Arrhythmia Agents; Cardiomyopathies; Child; Child, Preschool; Female; Flecainide; Heart Defects | 2015 |
Intravenous flecainide for the treatment of junctional ectopic tachycardia after surgery for congenital heart disease.
Topics: Anti-Arrhythmia Agents; Cardiac Surgical Procedures; Dose-Response Relationship, Drug; Drug Administ | 2003 |